Heberprot-P is a Cuban medicine for the treatment of diabetic foot ulcers. This medicine is available in more than ten countries. Currently, this medicine is not legally available in the United States, but it is in the testing process.
South Korean scientists have developed a transparent skin patch that can measure the glucose levels of the patient in the perspiration (instead of the blood). The patch can simultaneously inject the drugs through the microneedles.
The sensors in the patch can send the data collected from the perspiration (or sweat) to a Smartphone App. A need of the medication will be checked by the App. The App can pass instructions to the microneedles in the patch to deliver the drugs.
A trial on mice and another trial on humans are successful. Another trial is going to be conducted under a challenging condition. If the prototype is successful, then the patch could be available within a few years. It is expected that the cost of the patch is the same as the conventional diagnostic and treatment kit.
Dr. Melissa Schilling, Professor at the NYU Stern School of Business has found a connection between diabetes and Alzheimer's disease. The study shows that the hyperinsulinemia is responsible for almost half of Alzheimer's cases.
The researchers have analyzed the records of 2,525 participants, aged between 40 and 69 years for four-and-a-half years. The study has found that the depression combined with the risk of diabetes will further enhance the risk of type 2 diabetes. The study was published in the journal Molecular Psychiatry.
The Salk scientists have announced a cure to type 1 diabetes (T1D). The scientists have found that the ERR-gamma protein switch (which make lab-grown cells) is more responsive to glucose and can trigger the release of insulin at a normal rate.
Scientists have checked the new technology on mice models of type 1 diabetes (T1D) by transplanting the mature lab-grown beta cells with the ERR-gamma protein switch on. About half of the mice models of diabetes were found to be with the normal sugar (glucose) levels within two months.
If this technology is successful, one day, it is possible to grow the insulin-producing beta cells from pluripotent stem cells taken from the patients. This technology is a more practical, applicable and affordable to all people. This research was published in the journal Cell Metabolism.
The researchers examined patients with a liver disease for over ten years. The study shows that people with type 2 diabetes (T2D) may have three times increased the risk of liver disease compared with normal people.
The reason for the liver disease in patients of type 2 diabetes is due to the buildup of fat within the liver cells. The buildup of fat within the liver cells is called non-alcoholic fatty liver disease (NAFLD).
People can prevent NAFLD by following a proper diet. A team of researchers from the University of Southampton and the University of Edinburgh has participated in the study.
The National Center for Global Health and Medicine, Tokyo, hopes to transplant insulin-producing pig cells into the humans to cure type 1 diabetes (T1D) as the Japanese government has relaxed rules. They want to do this within three years.
Mississippi is the most obese state in the United States. As the obesity of the people is high, diabetes health care costs ($10,507, 4Th highest) and premature deaths (487 per 10,000) are also high. Incidentally, nine of the ten most obese states are in the south.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.